Hickish T, Mehta A, Liu MC, Huang CS, et al. Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Breast Cancer Res Treat 2022 Feb 9. pii: 10.1007/s10549-021-06449.
PMID: 35138529